Dr. Wages is an Associate Professor in the Division of Translational Research & Applied Statistics in the Department of Public Health Sciences. He is also an active member of the UVA Cancer Center Biostatistics Shared Resource. Dr. Wages is part of a national research effort to change the way early-phase clinical trials in oncology are done, not only through the pursuit of novel statistical methods, but also by focusing on successful implementation of developed methods into real studies. He collaborates with cancer center members in tailoring clinical trial designs to meet contemporary research objectives in early drug development.
Translational Research & Applied Statistics
Ph.D., Statistics, University of Virginia, 2010
P.O. Box 800717
West Complex Old Med School Room 3890
- Design, monitoring, and analysis of early-phase clinical trials in oncology.
- Associate Editor, Clinical Trials.
- Faculty member, ASCO/AACR Methods in Clinical Cancer Research Workshop; Vail, CO.
- Conquer Cancer Foundation Grants Selection Committee, Young Investigator Award Panel, ASCO.
- Introduction to Statistics lecture, Foundations of Medicine for incoming medical students
- Introduction to Biostatistics, Short course for Radiation Oncology residents and Hematology Oncology fellows
- Melssen MM, Petroni GR, Chianese-Bullock KA, Wages NA, et al. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients. J Immunother Cancer 2019; 7: 163. PMID: 31248461 .
- Hobbs B, Barata P, Kanjanapan Y, Paller C, Perlmutter J, Pond GR, Prowell T, Rubin E, Seymour L, Wages NA, et al. Seamless designs: current practice and considerations for early phase drug development in oncology. J Natl Cancer Inst 2019; 111: 118-28. PMID: 30561713.
- Wages NA, Chiuzan C, Panageas KS. Design considerations for early-phase clinical trials of immune-oncology agents. J Immunother Cancer 2018; 6: 81. PMCID: PMC6103998.
- Wages NA, Portell CA, Williams ME, Conaway MR, Petroni GR. Implementation of a model-based design in a phase 1b study of combined targeted agents. Clin Cancer Res 2017; 23: 7158-64. PMCID: PMC5712236.
- Wages NA, Slingluff CL, Jr, Petroni GR. Statistical controversies in clinical research. early-phase adaptive design for combination immunotherapies. Ann Oncol 2017; 35: 696-701. PMID: 28011450.